Model-Based Assessments of CYP-Mediated Drug-Drug Interaction Risk of Alectinib: Physiologically Based Pharmacokinetic Modeling Supported Clinical Development-Reference-Cited by-同舟云学术

Model-Based Assessments of CYP-Mediated Drug-Drug Interaction Risk of Alectinib: Physiologically Based Pharmacokinetic Modeling Supported Clinical Development

Published:2017-12-27 Issue:3 Volume:104 Page:505-514
ISSN:0009-9236
Container-title:Clinical Pharmacology & Therapeutics
language:en
Short-container-title:Clin. Pharmacol. Ther.

Author:

Cleary Yumi¹,Gertz Michael¹,Morcos Peter N.²,Yu Li²,Youdim Kuresh¹,Phipps Alex³,Fowler Stephen¹,Parrott Neil¹

Affiliation:

1. Roche Innovation Center; Basel Switzerland

2. Roche Innovation Center; New York New York USA

3. Roche Innovation Center; Welwyn UK

Publisher

Wiley

Subject

Pharmacology (medical),Pharmacology

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1002/cpt.956/fullpdf

Reference43 articles.

1. PMDA Report on the Deliberation Results (Evaluation and Licensing Division, Pharmaceutical and Food Safety Bureau, Ministry of Health, Labour and Welfare (Japan) http://www.pmda.go.jp/files/000208811.pdf 2014

2. FDA Approval Letter: Application Number 208434Orig1s000 http://www.accessdata.fda.gov/drugsatfda_docs/nda/2015/208434Orig1s000Approv.pdf 2015

3. EMA Summary of Opinion (initial authorisation) - Alecensa (alectinib) http://www.ema.europa.eu/docs/en_GB/document_library/Summary_of_opinion_-_Initial_authorisation/human/004164/WC500218188.pdf 2016

4. Metabolites of alectinib in human: their identification and pharmacological activity;Sato-Nakai;Heliyon,2017

5. Preclinical evaluation of the potential for cytochrome P450 inhibition and induction of the selective ALK inhibitor, alectinib;Sekiguchi;Xenobiotica,2017

Cited by 20 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Evaluation of the potential impact on pharmacokinetics of various cytochrome P450 substrates of increasing IL‐6 levels following administration of the T‐cell bispecific engager glofitamab;CPT: Pharmacometrics & Systems Pharmacology;2023-12-14

2. Prediction of pharmacokinetics of an anaplastic lymphoma kinase inhibitor in rat and monkey: application of physiologically based pharmacokinetic model as an alternative tool to minimise animal studies;Xenobiotica;2023-12-02

3. Application of physiologically based pharmacokinetics modeling in the research of small-molecule targeted anti-cancer drugs;Cancer Chemotherapy and Pharmacology;2023-07-19

4. An update on Alectinib: a first line treatment for ALK-positive advanced lung cancer;Expert Opinion on Pharmacotherapy;2023-06-13

5. Effects of drug-drug interactions and CYP3A4 variants on alectinib metabolism;Archives of Toxicology;2023-05-20